Director of Janux Therapeutics (JANX) receives new RSU and stock option awards

Rhea-AI Filing Summary

Janux Therapeutics director Winston Kung received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, and 15,500 stock options with an exercise price of $13.66 per share.

The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. The options vest in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual meeting, also subject to continued service. After the grant, Kung directly holds 11,750 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kung Winston

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,500	$0.00	--
Grant/Award	Common Stock	5,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 15,500 shares (Direct, null); Common Stock — 11,750 shares (Direct, null)

Footnotes (1)

1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Key Figures

RSU grant size: 5,500 shares Option grant size: 15,500 options Option exercise price: $13.66 per share +4 more

7 metrics

RSU grant size 5,500 shares Restricted stock units granted to director on June 11, 2026

Option grant size 15,500 options Stock options granted to director on June 11, 2026

Option exercise price $13.66 per share Strike price of stock options expiring June 10, 2036

Shares held after grant 11,750 shares Director’s direct common stock holdings following RSU grant

RSU vesting date June 11, 2027 Latest vesting date or earlier next annual stockholder meeting

Option vesting schedule 12 monthly installments Over 12 months following June 11, 2026, subject to service

Option expiration June 10, 2036 Expiration date of granted stock options

Key Terms

restricted stock units ("RSUs"), Stock Option (right to buy), continuous service, annual meeting of the Issuer's stockholders

4 terms

restricted stock units ("RSUs") financial

"Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 13.6600 per share"

continuous service financial

"subject to the Reporting Person's continuous service on such date"

annual meeting of the Issuer's stockholders financial

"the date of the next annual meeting of the Issuer's stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 08:00 PM Accepted by SEC EDGAR 06/12/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kung Winston

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		5,500(1)	A	$0	11,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.66	06/11/2026		A		15,500		(2)	06/10/2036	Common Stock	15,500	$0	15,500	D

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

2. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

	/s/ James Pennington, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Janux Therapeutics (JANX) director Winston Kung receive in this Form 4?

Winston Kung received 5,500 restricted stock units and 15,500 stock options in Janux Therapeutics. These are compensation-related equity awards, not open-market purchases or sales, and increase his potential ownership tied to future service and vesting conditions.

How do the new RSUs for Janux Therapeutics (JANX) director vest?

The 5,500 RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting. Vesting is conditioned on Winston Kung’s continuous service with Janux Therapeutics through the applicable vesting date, aligning his compensation with ongoing board service.

What are the terms of the new stock options reported for JANX?

Winston Kung received 15,500 stock options with an exercise price of $13.66 per share. The options vest in equal monthly installments over the 12 months following June 11, 2026, or sooner by the next annual meeting, subject to continued service.

How many Janux Therapeutics (JANX) shares does Winston Kung hold after these awards?

Following the RSU grant, Winston Kung directly holds 11,750 shares of common stock in Janux Therapeutics. This figure reflects his reported direct ownership after the non-cash equity awards disclosed in the Form 4 filing.

Are the equity awards to Janux Therapeutics (JANX) director open-market transactions?

No, the awards are compensation grants, not open-market trades. The Form 4 uses transaction code “A” for grant or award, indicating company-issued RSUs and options rather than purchases or sales on a stock exchange.